BIOMAT Database Logo BIOMAT Database Logo

Continuous arteriovenous hemofiltration with low-molecular-weight heparin. 1985

B Hory, and A Cachoux, and F Toulemonde

UI MeSH Term Description Entries
D001769 Blood The body fluid that circulates in the vascular system (BLOOD VESSELS). Whole blood includes PLASMA and BLOOD CELLS.
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014462 Ultrafiltration The separation of particles from a suspension by passage through a filter with very fine pores. In ultrafiltration the separation is accomplished by convective transport; in DIALYSIS separation relies instead upon differential diffusion. Ultrafiltration occurs naturally and is a laboratory procedure. Artificial ultrafiltration of the blood is referred to as HEMOFILTRATION or HEMODIAFILTRATION (if combined with HEMODIALYSIS).

Related Publications

B Hory, and A Cachoux, and F Toulemonde
Low-molecular-weight heparin for anticoagulation during continuous venovenous hemofiltration.
April 2003, Archives of internal medicine,
B Hory, and A Cachoux, and F Toulemonde
Continuous hemofiltration with a low molecular weight heparin, enoxaparine: report on two cases.
March 1991, International journal of clinical pharmacology, therapy, and toxicology,
B Hory, and A Cachoux, and F Toulemonde
Low molecular weight heparin in hemodialysis and hemofiltration patients.
November 1985, Kidney international,
B Hory, and A Cachoux, and F Toulemonde
Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration.
April 1988, Kidney international,
B Hory, and A Cachoux, and F Toulemonde
Hemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltration rates.
January 2009, Critical care (London, England),
B Hory, and A Cachoux, and F Toulemonde
Continuous arteriovenous hemofiltration.
January 1984, Critical care nurse,
B Hory, and A Cachoux, and F Toulemonde
Continuous arteriovenous hemofiltration.
July 1990, The Medical clinics of North America,
B Hory, and A Cachoux, and F Toulemonde
[Continuous arteriovenous hemofiltration].
February 1986, Tijdschrift voor ziekenverpleging,
B Hory, and A Cachoux, and F Toulemonde
Continuous arteriovenous hemofiltration.
September 1987, Critical care medicine,
B Hory, and A Cachoux, and F Toulemonde
Continuous arteriovenous ultrafiltration versus continuous arteriovenous hemofiltration.
May 1984, The International journal of artificial organs,
Copied contents to your clipboard!